Polar Capital Holdings’s Aptose Biosciences, Inc. APTO Stock Holding History

Polar Capital Holdings’s Portfolio APTO Stock Details APTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-5,742	Closed	-$8.58K	–	379
2021 Q2	$8.58K	Buy	5,742 +1,667	+41%	+$3.63M	0.04%	242
2021 Q1	$11M	Buy	4,075 +63	+2%	+$125K	0.07%	200
2020 Q4	$7.91M	Buy	+4,012	New	+$9.43M	0.05%	224

Other funds holding APTO

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PAWC

P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return

Polar Capital Holdings's APTO Position: Q3 2021 in Review

Polar Capital Holdings sold out of Aptose Biosciences, Inc. (APTO) in Q3 2021, closing a stake of 5,742 shares — an estimated $8.58K sold.

Polar Capital Holdings first reported a position in APTO in Q4 2020 and held it in 3 quarters. The position peaked at $11M in Q1 2021. 64 funds tracked by Wall St. Rank hold APTO as of Q3 2021.

Polar Capital Holdings reported no remaining Aptose Biosciences, Inc. position as of Q3 2021 after selling out during the quarter.
Polar Capital Holdings sold 5,742 Aptose Biosciences, Inc. shares in Q3 2021, an estimated $8.58K.
Polar Capital Holdings first reported a position in Aptose Biosciences, Inc. in Q4 2020 and held it in 3 quarters.
Polar Capital Holdings's Aptose Biosciences, Inc. position peaked at $11M in Q1 2021.
64 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q3 2021.

Based on Polar Capital Holdings's 13F filing for Q3 2021, filed 15 Nov 2021.